These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22609485)

  • 1. Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm.
    Hussain T; Kneeshaw PJ
    Int J Surg; 2012; 10(6):313-6. PubMed ID: 22609485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cerebrovascular risks associated with tamoxifen use.
    Bushnell C
    Expert Opin Drug Saf; 2005 May; 4(3):501-7. PubMed ID: 15934856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for breast cancer.
    Karn A; Jha AK; Shrestha S; Acharya B; Poudel S; Bhandari RB
    JNMA J Nepal Med Assoc; 2010; 49(177):62-7. PubMed ID: 21180225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke risk and tamoxifen therapy for breast cancer.
    Geiger AM; Fischberg GM; Chen W; Bernstein L
    J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
    Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
    Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
    Fink AK; Gurwitz J; Rakowski W; Guadagnoli E; Silliman RA
    J Clin Oncol; 2004 Aug; 22(16):3309-15. PubMed ID: 15310774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
    Chahine G; Howayek M; Atallah D
    J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral swollen eyelids occurring during adjuvant treatment with tamoxifen for early breast cancer.
    Jaspers H; Blaisse R; Maessen-Visch B; Mattijssen V
    Neth J Med; 2009 Jun; 67(6):245-6. PubMed ID: 19749398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.